Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
MLYS
MLYS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest MLYS ETF News Today | Earnings, Events & Price Alerts
MLYS News
Chronic Kidney Disease Market Growth Drivers
17h ago
Newsfilter
MLYS Stock 52-Week Highs and Lows Analysis
Feb 13 2026
NASDAQ.COM
Mineralys Grants Stock Options to New Employees
Feb 12 2026
Newsfilter
Medical Properties Trust Options Volume Surges 120.3% Today
Jan 07 2026
NASDAQ.COM
Mineralys Highlights Lorundrostat Clinical Progress, Anticipates 2026 Data Release
Jan 06 2026
Globenewswire
Mineralys Therapeutics (MLYS) Shares Oversold with RSI at 29.3
Dec 30 2025
NASDAQ.COM
Mineralys Therapeutics Inc Offers 16.1% Annualized Return on $22.50 Put Option
Dec 29 2025
NASDAQ.COM
UnitedHealth Group Options Volume Surges to 67,042 Contracts
Dec 26 2025
NASDAQ.COM
Mineralys Therapeutics Shares Surge 203.4%, NDA Submission Expected in 2026
Dec 26 2025
NASDAQ.COM
Suvretta Capital Increases Mineralys Stake by 387,641 Shares Worth $57.25 Million
Dec 23 2025
Fool
Suvretta Capital Increases MLYS Stake by 387,641 Shares, Valued at $57.25 Million
Dec 23 2025
NASDAQ.COM
Mineralys' Lorundrostat for Treatment-Resistant Hypertension Recognized by JAMA as Key Study
Dec 12 2025
Globenewswire
Mineralys' lorundrostat for Treatment-Resistant Hypertension Recognized by JAMA as Key Research of 2025
Dec 12 2025
Newsfilter
Significant Wednesday Options Trading: CPRI, AXP, MLYS
Dec 03 2025
NASDAQ.COM
HC Wainwright & Co. Reaffirms Buy Rating for Mineralys Therapeutics and Increases Price Target to $56
Nov 12 2025
Benzinga
Wells Fargo Continues Overweight Rating for Mineralys Therapeutics (MLYS)
Nov 12 2025
NASDAQ.COM
Show More News
